Semaglutide: Research Overview, Mechanisms, and Current Evidence
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved by the US FDA as a prescription drug for type 2 diabetes (Ozempic, Rybelsus) and for chronic weight management (Wegovy), where it is given as a once-weekly subcutaneous injection or daily oral tablet. Because it is a prescription drug, the framing here is research-use only. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Semaglutide is a prescription drug. Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
Semaglutide mimics the incretin hormone GLP-1, acting on GLP-1 receptors to influence blood sugar control, appetite, and gastric emptying.
- Activates the GLP-1 receptor, enhancing glucose-dependent insulin release from the pancreas.
- Reported to reduce appetite and food intake through central nervous system pathways.
- Slows gastric emptying, contributing to increased satiety.
- Studied for downstream improvements in body weight, blood pressure, and lipid and glycemic markers.
Areas of Research Interest
Published studies have examined semaglutide across diabetes, obesity, and cardiometabolic health in large clinical trial programs.
Chronic weight management
Studied in the Phase III STEP program for substantial weight reduction in people with overweight or obesity.
Type 2 diabetes
Approved and studied for glycemic control as a once-weekly injection or daily oral tablet.
Cardiometabolic risk
Examined for effects on blood pressure, lipids, and inflammatory markers alongside weight loss.
Comparative effectiveness
Compared head-to-head with tirzepatide in the SURMOUNT-5 trial of weight management.
Reported Study Parameters
For laboratory research use only. The table below reports the doses and routes used in published clinical trials and approved labeling, with sources. It describes what was administered in those studies and is not a protocol, recommendation, or guidance for use in humans or animals. Because semaglutide is a prescription drug, this information is provided for research context only.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| Adults with overweight or obesity (Phase III STEP program) | Once-weekly subcutaneous semaglutide 2.4 mg | Amaro 2022·DOI |
| Weight management, head-to-head vs tirzepatide (Phase III SURMOUNT-5) | Semaglutide at maximum tolerated dose, once-weekly subcutaneous | Johansson 2026·DOI |
| Human research (regulatory status) | FDA-approved as semaglutide (Ozempic and Rybelsus for type 2 diabetes; Wegovy for chronic weight management); a prescription drug provided here for research use only | Altes 2026·DOI |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2022 to 2026)
Peer-reviewed literature indexed on PubMed documents large clinical trial programs and comparative studies of semaglutide for weight and metabolic health.
STEP program (weight and cardiometabolic markers)
A 2022 review of the global Phase III STEP program reported that once-weekly subcutaneous semaglutide 2.4 mg produced greater reductions than placebo in body weight, waist circumference, BMI, and blood pressure across the STEP 1 to 5 trials. PubMed·DOI
Head-to-head with tirzepatide (SURMOUNT-5)
A 2026 cost-effectiveness analysis using head-to-head SURMOUNT-5 Phase III data compared semaglutide and tirzepatide at maximum tolerated doses for weight management in people without type 2 diabetes. PubMed·DOI
Health-economic modeling
A 2026 analysis modeled semaglutide 2.4 mg plus diet and exercise using STEP 1 efficacy data, estimating it to be a cost-effective option for adults with obesity from a national health system perspective in Spain. PubMed·DOI
Research Questions
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It mimics the incretin hormone GLP-1.
What is the current state of human evidence?
The Phase III STEP and SUSTAIN programs established large, sustained effects on weight and blood sugar. Semaglutide is FDA-approved for specific indications and widely studied.
What does the available safety literature suggest?
Common adverse effects are gastrointestinal (nausea, vomiting, diarrhea), mostly during dose escalation. It carries specific contraindications and warnings, so it should be used only under medical supervision.
Referenced Citations
Literature indexed on PubMed.
- Amaro, A., Skolnik, N.S., & Sugimoto, D. (2022). Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad. Med., 134(sup1), 18-27. PubMed·DOI
- Johansson, E., et al. (2026). Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial. J. Med. Econ., 29(1), 1258-1278. PubMed·DOI
- Altes, A., et al. (2026). Once-weekly subcutaneous semaglutide 2.4 mg injection is cost-effective for weight management in Spain. Adv. Ther. PubMed·DOI
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.